INKT earnings analysis
What we found in INKT's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
MiNK reported Q2 2026 EPS of negative $0.62, missing the negative $0.60 consensus estimate, while net loss improved to $3.1 million from $4.2 million year over year. Cash declined to $8.8 million, and the filing provides no formal quantitative revenue or EPS guidance. Preliminary agenT-797 Day 28 observations were positive, but the small patient sample and lack of additional data until early 2027 leave substantial clinical and financing uncertainty.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Year-over-year loss improved
- Q2 2026 EPS was a loss of $0.62, compared with a loss of $1.06 in Q2 2025 and a loss of $0.57 in Q1 2026; EPS missed the $0.60 loss consensus estimate by $0.02.
- Net loss narrowed year over year
- Net loss improved to $3.1 million from $4.2 million in the prior-year quarter, a $1.1 million improvement.
- Early clinical observations positive
- Preliminary Day 28 observations for agenT-797 were positive, with additional data expected in early 2027.
- No material control weaknesses reported
- Management concluded disclosure controls were effective as of June 30, 2026, and reported no changes during the quarter that materially affected internal control over financial reporting.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Cash balance continues to decline
- Cash declined to $8.8 million, increasing financing and liquidity risk for the development program.
- Clinical evidence remains preliminary
- The positive agenT-797 Day 28 observations are preliminary and based on a small number of patients; additional data are not expected until early 2027.
- No new risk disclosures, existing risks remain
- The filing states there were no material changes to the risk factors in the 2025 Form 10-K, but also warns that legal proceedings could adversely affect business, results, financial condition or cash flows.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.62
What they said about what is next.
No formal quantitative revenue or EPS guidance was provided; additional agenT-797 trial data are expected in early 2027.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 15, 2026
- MiNK Therapeutics reported a net loss of $1.7 million for Q1 2026, with an EPS of -0.56, beating consensus estimates of -0.68. The company has maintained a cash balance of $9.5 million but faces ongoing operating losses…
- 10-K · March 31, 2026
- MiNK Therapeutics positions itself as a platform company developing allogeneic, off-the-shelf iNKT cell therapies (lead candidate agenT-797) across oncology, critical pulmonary immune failure and GvHD, while also…
- 10-Q · August 14, 2025
- MiNK Therapeutics reported no revenue for Q2 2025 with a significant net loss of $4.24 million, growing from a loss of $2.70 million in the prior year. Operating expenses increased notably, driven by research and…
- 10-Q · May 15, 2025
- MiNK Therapeutics reported improved operating and per-share results in Q1 2025 with net loss narrowing to $(2,766,697) (EPS $(0.70)) versus $(3,813,295) (EPS $(1.10)) in Q1 2024. The improvement was driven by a sharp…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing INKT makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever